Intravenous Iron Therapy Prevents Heart Failure Rehospitalizations

Intravenous (IV) ferric carboxymaltose reduced subsequent hospitalizations among patients with acute heart failure and iron deficiency, according to a 15-country trial in The Lancet. Patients with acute heart failure often have iron deficiency, which contributes to poor prognosis regardless of anemia.
Source: JAMA - Category: General Medicine Source Type: research